Prostate Health Market [Disease Type: Prostatitis, Benign Prostatic Hyperplasia (BPH), and Prostate Cancer (Adenocarcinoma, Transitional Cell Carcinoma, Squamous Cell Carcinoma, and Small Cell Prostate Cancer)] - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
Prostate Health Market – Scope of Report TMR’s report on the global prostate health market studies the past as well as the current growth trends and opportunities to gain valuable insights of the ... もっと見る
日本語のページは自動翻訳を利用し作成しています。
SummaryProstate Health Market – Scope of ReportTMR’s report on the global prostate health market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global prostate health market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global prostate health market from 2024 to 2034. The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the prostate health market. Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global prostate health market. The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global prostate health market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global prostate health market. The report delves into the competitive landscape of the global prostate health market. Key players operating in the global prostate health market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global prostate health market profiled in this report. Key Questions Answered in Global prostate health Market Report • What is the sales/revenue generated by prostate health across all regions during the forecast period? • What are the opportunities in the global prostate health market? • What are the major drivers, restraints, opportunities, and threats in the market? • Which regional market is set to expand at the fastest CAGR during the forecast period? • Which segment is expected to generate the highest revenue globally in 2034? • Which segment is projected to expand at the highest CAGR during the forecast period? • What are the market positions of different companies operating in the global market? Prostate Health Market – Research Objectives and Research Approach The comprehensive report on the global prostate health market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products. For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period. The report analyzes the global prostate health market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global prostate health market. Table of Contents1. Preface1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Global Prostate Health Market 4. Market Overview 4.1. Introduction 4.1.1. Segment Definition 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. Global Prostate Health Market Analysis and Forecast, 2020-2034 4.4.1. Market Revenue Projections (US$ Mn) 5. Key Insights 5.1. Regulatory Scenario by region/globally 5.2. Key Industry Events (Product Launches, Collaborations and Partnerships, Acquisitions, Approvals etc.) 5.3. Pipeline Analysis 5.4. Reimbursement Scenario by Key Countries 5.5. Disease Diagnosis of Prostate Diseases (Prostatitis, Benign Prostate Hyperplasia, Prostate Cancer, etc.) 5.6. Brand Analysis 5.7. Pricing Analysis 5.8. Covid-19 Pandemic Impact on Industry 6. Global Prostate Health Market Analysis and Forecast, by Disease Type 6.1. Introduction & Definition 6.2. Key Findings/Developments 6.3. Market Value Forecast, by Disease Type, 2020-2034 6.3.1. Prostatitis 6.3.2. Benign Prostatic Hyperplasia (BPH) 6.3.3. Prostate Cancer 6.3.3.1. Adenocarcinoma 6.3.3.2. Transitional Cell Carcinoma 6.3.3.3. Squamous Cell Carcinoma 6.3.3.4. Small Cell Prostate Cancer 6.4. Market Attractiveness Analysis, by Disease Type 7. Global Prostate Health Market Analysis and Forecast, by Treatment 7.1. Introduction & Definition 7.2. Key Findings/Developments 7.3. Market Value Forecast, by Treatment, 2020-2034 7.3.1. Chemotherapy 7.3.2. Hormone Therapy 7.3.3. Immunotherapy 7.4. Market Attractiveness Analysis, by Treatment 8. Global Prostate Health Market Analysis and Forecast, by Route of Administration 8.1. Introduction & Definition 8.2. Key Findings/Developments 8.3. Market Value Forecast, by Route of Administration, 2020-2034 8.3.1. Oral 8.3.2. Parenteral 8.4. Market Attractiveness Analysis, by Route of Administration 9. Global Prostate Health Market Analysis and Forecast, by Distribution Channel 9.1. Introduction & Definition 9.2. Key Findings/Developments 9.3. Market Value Forecast, by Distribution Channel, 2020-2034 9.3.1. Hospital Pharmacies 9.3.2. Retail Pharmacies 9.3.3. Online Pharmacies 9.4. Market Attractiveness Analysis, by Distribution Channel 10. Global Prostate Health Market Analysis and Forecast, by Region 10.1. Key Findings 10.2. Market Value Forecast, by Region, 2020-2034 10.2.1. North America 10.2.2. Europe 10.2.3. Asia Pacific 10.2.4. Latin America 10.2.5. Middle East & Africa 10.3. Market Attractiveness By Region 11. North America Prostate Health Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Market Value Forecast, by Disease Type, 2020-2034 11.2.1. Prostatitis 11.2.2. Benign Prostatic Hyperplasia (BPH) 11.2.3. Prostate Cancer 11.2.3.1. Adenocarcinoma 11.2.3.2. Transitional Cell Carcinoma 11.2.3.3. Squamous Cell Carcinoma 11.2.3.4. Small Cell Prostate Cancer 11.3. Market Value Forecast, by Treatment, 2020-2034 11.3.1. Chemotherapy 11.3.2. Hormone Therapy 11.3.3. Immunotherapy 11.4. Market Value Forecast, by Route of Administration, 2020-2034 11.4.1. Oral 11.4.2. Parenteral 11.5. Market Value Forecast, by Distribution Channel, 2020-2034 11.5.1. Hospital Pharmacies 11.5.2. Retail Pharmacies 11.5.3. Online Pharmacies 11.6. Market Value Forecast, by Country 11.6.1. U.S. 11.6.2. Canada 11.7. Market Attractiveness Analysis 11.7.1. By Disease Type 11.7.2. By Treatment 11.7.3. By Route of Administration 11.7.4. By Distribution Channel 11.7.5. By Country 12. Europe Prostate Health Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.2. Market Value Forecast, by Disease Type, 2020-2034 12.2.1. Prostatitis 12.2.2. Benign Prostatic Hyperplasia (BPH) 12.2.3. Prostate Cancer 12.2.3.1. Adenocarcinoma 12.2.3.2. Transitional Cell Carcinoma 12.2.3.3. Squamous Cell Carcinoma 12.2.3.4. Small Cell Prostate Cancer 12.3. Market Value Forecast, by Treatment, 2020-2034 12.3.1. Chemotherapy 12.3.2. Hormone Therapy 12.3.3. Immunotherapy 12.4. Market Value Forecast, by Route of Administration, 2020-2034 12.4.1. Oral 12.4.2. Parenteral 12.5. Market Value Forecast, by Distribution Channel, 2020-2034 12.5.1. Hospital Pharmacies 12.5.2. Retail Pharmacies 12.5.3. Online Pharmacies 12.6. Market Value Forecast, by Country/Sub-region, 2020-2034 12.6.1. Germany 12.6.2. UK 12.6.3. France 12.6.4. Italy 12.6.5. Spain 12.6.6. Rest of Europe 12.7. Market Attractiveness Analysis 12.7.1. By Disease Type 12.7.2. By Treatment 12.7.3. By Route of Administration 12.7.4. By Distribution Channel 12.7.5. By Country/Sub-region 13. Asia Pacific Prostate Health Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.2. Market Value Forecast, by Disease Type, 2020-2034 13.2.1. Prostatitis 13.2.2. Benign prostatic hyperplasia (BPH) 13.2.3. Prostate Cancer 13.2.3.1. Adenocarcinoma 13.2.3.2. Transitional Cell Carcinoma 13.2.3.3. Squamous Cell Carcinoma 13.2.3.4. Small Cell Prostate Cancer 13.3. Market Value Forecast, by Treatment, 2020-2034 13.3.1. Chemotherapy 13.3.2. Hormone Therapy 13.3.3. Immunotherapy 13.4. Market Value Forecast, by Route of Administration, 2020-2034 13.4.1. Oral 13.4.2. Parenteral 13.5. Market Value Forecast, by Distribution Channel, 2020-2034 13.5.1. Hospital Pharmacies 13.5.2. Retail Pharmacies 13.5.3. Online Pharmacies 13.6. Market Value Forecast, by Country/Sub-region, 2020-2034 13.6.1. China 13.6.2. Japan 13.6.3. India 13.6.4. Australia & New Zealand 13.6.5. Rest of Asia Pacific 13.7. Market Attractiveness Analysis 13.7.1. By Disease Type 13.7.2. By Treatment 13.7.3. By Route of Administration 13.7.4. By Distribution Channel 13.7.5. By Country/Sub-region 14. Latin America Prostate Health Market Analysis and Forecast 14.1. Introduction 14.1.1. Key Findings 14.2. Market Value Forecast, by Disease Type, 2020-2034 14.2.1. Prostatitis 14.2.2. Benign prostatic hyperplasia (BPH) 14.2.3. Prostate Cancer 14.2.3.1. Adenocarcinoma 14.2.3.2. Transitional Cell Carcinoma 14.2.3.3. Squamous Cell Carcinoma 14.2.3.4. Small Cell Prostate Cancer 14.3. Market Value Forecast, by Treatment, 2020-2034 14.3.1. Chemotherapy 14.3.2. Hormone Therapy 14.3.3. Immunotherapy 14.4. Market Value Forecast, by Route of Administration, 2020-2034 14.4.1. Oral 14.4.2. Parenteral 14.5. Market Value Forecast, by Distribution Channel, 2020-2034 14.5.1. Hospital Pharmacies 14.5.2. Retail Pharmacies 14.5.3. Online Pharmacies 14.6. Market Value Forecast, by Country/Sub-region, 2020-2034 14.6.1. Brazil 14.6.2. Mexico 14.6.3. Rest of Latin America 14.7. Market Attractiveness Analysis 14.7.1. By Disease Type 14.7.2. By Treatment 14.7.3. By Route of Administration 14.7.4. By Distribution Channel 14.7.5. By Country/Sub-region 15. Middle East & Africa Prostate Health Market Analysis and Forecast 15.1. Introduction 15.1.1. Key Findings 15.2. Market Value Forecast, by Disease Type, 2020-2034 15.2.1. Prostatitis 15.2.2. Benign prostatic hyperplasia (BPH) 15.2.3. Prostate Cancer 15.2.3.1. Adenocarcinoma 15.2.3.2. Transitional Cell Carcinoma 15.2.3.3. Squamous Cell Carcinoma 15.2.3.4. Small Cell Prostate Cancer 15.3. Market Value Forecast, by Treatment, 2020-2034 15.3.1. Chemotherapy 15.3.2. Hormone Therapy 15.3.3. Immunotherapy 15.4. Market Value Forecast, by Route of Administration, 2020-2034 15.4.1. Oral 15.4.2. Parenteral 15.5. Market Value Forecast, by Distribution Channel, 2020-2034 15.5.1. Hospital Pharmacies 15.5.2. Retail Pharmacies 15.5.3. Online Pharmacies 15.6. Market Value Forecast, by Country/Sub-region, 2020-2034 15.6.1. GCC Countries 15.6.2. South Africa 15.6.3. Rest of Middle East & Africa 15.7. Market Attractiveness Analysis 15.7.1. By Disease Type 15.7.2. By Treatment 15.7.3. By Route of Administration 15.7.4. By Distribution Channel 15.7.5. By Country/Sub-region 16. Competition Landscape 16.1. Market Player - Competition Matrix (By Tier and Size of companies) 16.2. Market Share Analysis By Company (2023) 16.3. Company Profiles 16.3.1. Abbott Laboratories 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.1.2. Product Portfolio 16.3.1.3. Financial Overview 16.3.1.4. SWOT Analysis 16.3.1.5. Strategic Overview 16.3.2. Amgen Inc. 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.2.2. Product Portfolio 16.3.2.3. Financial Overview 16.3.2.4. SWOT Analysis 16.3.2.5. Strategic Overview 16.3.3. Astellas Pharma Inc. 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.3.2. Product Portfolio 16.3.3.3. Financial Overview 16.3.3.4. SWOT Analysis 16.3.3.5. Strategic Overview 16.3.4. AstraZeneca PLC 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.4.2. Product Portfolio 16.3.4.3. Financial Overview 16.3.4.4. SWOT Analysis 16.3.4.5. Strategic Overview 16.3.5. Bayer AG 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.5.2. Product Portfolio 16.3.5.3. Financial Overview 16.3.5.4. SWOT Analysis 16.3.5.5. Strategic Overview 16.3.6. Bristol-Myers Squibb (BMS) 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.6.2. Product Portfolio 16.3.6.3. Financial Overview 16.3.6.4. SWOT Analysis 16.3.6.5. Strategic Overview 16.3.7. Eli Lilly and Company 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.7.2. Product Portfolio 16.3.7.3. Financial Overview 16.3.7.4. SWOT Analysis 16.3.7.5. Strategic Overview 16.3.8. Ferring Pharmaceuticals 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.8.2. Product Portfolio 16.3.8.3. Financial Overview 16.3.8.4. SWOT Analysis 16.3.8.5. Strategic Overview 16.3.9. GSK PLC. 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.9.2. Product Portfolio 16.3.9.3. Financial Overview 16.3.9.4. SWOT Analysis 16.3.9.5. Strategic Overview 16.3.10. Johnson & Johnson 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.10.2. Product Portfolio 16.3.10.3. Financial Overview 16.3.10.4. SWOT Analysis 16.3.10.5. Strategic Overview 16.3.11. Merck and Co. Inc. 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.11.2. Product Portfolio 16.3.11.3. Financial Overview 16.3.11.4. SWOT Analysis 16.3.11.5. Strategic Overview 16.3.12. Pfizer Inc. 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.12.2. Product Portfolio 16.3.12.3. Financial Overview 16.3.12.4. SWOT Analysis 16.3.12.5. Strategic Overview 16.3.13. Siemens Healthineers AG 16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.13.2. Product Portfolio 16.3.13.3. Financial Overview 16.3.13.4. SWOT Analysis 16.3.13.5. Strategic Overview
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(その他)の最新刊レポートTransparency Market Research 社の最新刊レポート
本レポートと同じKEY WORD(industry)の最新刊レポート
よくあるご質問Transparency Market Research社はどのような調査会社ですか?トレンスペアレンシーマーケットリサーチ(Transparency Market Research /TMR)は市場参入やホワイトスペースの特定、新商品や新サービスの立ち上げ、戦略的M&Aなどの実現のた... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/09/25 10:28 144.33 円 161.91 円 196.41 円 |